Ahmed Sawas

Hematology
161 Fort Washington Ave
New York, NY 10032

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 39 publications

Treatment intensity, illness burden, and disparities in newly diagnosed diffuse large B-cell lymphoma treated at an urban academic center.

Treatment intensity, illness burden, and disparities in newly diagnosed diffuse large B-cell lymphoma treated at an urban academic center.

Journal: Leukemia & lymphoma
Published: June 07, 2026

Clinical outcomes of mature T- and NK-cell lymphomas in hepatitis B virus positive individuals: results from the PETAL Global Consortium.

Clinical outcomes of mature T- and NK-cell lymphomas in hepatitis B virus positive individuals: results from the PETAL Global Consortium.

Journal: Leukemia & lymphoma
Published: March 14, 2026

Real-world clinical outcomes in patients with CLL previously treated with covalent BTKi and BCL2i regimens.

Real-world clinical outcomes in patients with CLL previously treated with covalent BTKi and BCL2i regimens.

Journal: Blood neoplasia
Published: October 24, 2025

Outcomes of relapsed/refractory peripheral T-cell lymphoma in the modern era: impact of stem cell transplant and novel agents.

Outcomes of relapsed/refractory peripheral T-cell lymphoma in the modern era: impact of stem cell transplant and novel agents.

Journal: Leukemia & lymphoma
Published: August 14, 2025

Life-Threatening Cytopenias in a Jehovah's Witness Following CD19-Directed Chimeric Antigen Receptor T Cell Therapy.

Life-Threatening Cytopenias in a Jehovah's Witness Following CD19-Directed Chimeric Antigen Receptor T Cell Therapy.

Journal: EJHaem
Published: February 26, 2025

Forecasting optimal treatments in relapsed/refractory mature T- and NK-cell lymphomas: A global PETAL Consortium study.

Forecasting optimal treatments in relapsed/refractory mature T- and NK-cell lymphomas: A global PETAL Consortium study.

Journal: British journal of haematology
Published: February 12, 2025

Posttransplant rituximab exposure and risk of PTLD in solid organ transplant recipients with EBV DNAemia.

Posttransplant rituximab exposure and risk of PTLD in solid organ transplant recipients with EBV DNAemia.

Journal: Blood neoplasia
Published: January 15, 2025

Global outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: results from the PETAL consortium.

Global outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: results from the PETAL consortium.

Journal: Blood advances
Published: August 29, 2024

A Phase II Study of Acimtamig (AFM13) in Patients with CD30-Positive, Relapsed, or Refractory Peripheral T-cell Lymphomas.

A Phase II Study of Acimtamig (AFM13) in Patients with CD30-Positive, Relapsed, or Refractory Peripheral T-cell Lymphomas.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: July 03, 2024

Phase II study of the novel antifolate agent pralatrexate in combination with the histone deacetylase inhibitor romidepsin for the treatment of patients with mature T-cell lymphoma.

Phase II study of the novel antifolate agent pralatrexate in combination with the histone deacetylase inhibitor romidepsin for the treatment of patients with mature T-cell lymphoma.

Journal: Leukemia & lymphoma
Published: March 22, 2024

Applying the estimand and target trial frameworks to external control analyses using observational data: a case study in the solid tumor setting.

Applying the estimand and target trial frameworks to external control analyses using observational data: a case study in the solid tumor setting.

Journal: Frontiers in pharmacology
Published: May 16, 2023

RWD-derived response in multiple myeloma.

RWD-derived response in multiple myeloma.

Journal: PloS one
Published: October 21, 2022
Showing 1-12 of 39

Last Updated: 09/26/2026